453 related articles for article (PubMed ID: 3330421)
1. Lipoproteins and atherosclerosis.
Babiak J; Rudel LL
Baillieres Clin Endocrinol Metab; 1987 Aug; 1(3):515-50. PubMed ID: 3330421
[TBL] [Abstract][Full Text] [Related]
2. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
3. Cholesteryl ester transfer activity in liver disease and cholestasis, and its relation with fatty acid composition of lipoprotein lipids.
Iglesias A; Arranz M; Alvarez JJ; Perales J; Villar J; Herrera E; Lasunción MA
Clin Chim Acta; 1996 Apr; 248(2):157-74. PubMed ID: 8740580
[TBL] [Abstract][Full Text] [Related]
4. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
Guerin M; Lassel TS; Le Goff W; Farnier M; Chapman MJ
Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817
[TBL] [Abstract][Full Text] [Related]
5. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
[TBL] [Abstract][Full Text] [Related]
6. Effect of lipid transfer protein on plasma lipids, apolipoproteins and metabolism of high-density lipoprotein cholesteryl ester in the rat.
Groener JE; van Gent T; van Tol A
Biochim Biophys Acta; 1989 Mar; 1002(1):93-100. PubMed ID: 2493808
[TBL] [Abstract][Full Text] [Related]
7. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
Guerin M; Le Goff W; Frisdal E; Schneider S; Milosavljevic D; Bruckert E; Chapman MJ
J Clin Endocrinol Metab; 2003 Aug; 88(8):3738-46. PubMed ID: 12915663
[TBL] [Abstract][Full Text] [Related]
8. Atherogenic hyperlipoproteinemia. The cellular and molecular biology of plasma lipoproteins altered by dietary fat and cholesterol.
Mahley RW
Med Clin North Am; 1982 Mar; 66(2):375-402. PubMed ID: 7040843
[TBL] [Abstract][Full Text] [Related]
9. [Molecular biology of reverse cholesterol transport system and impairment of the protection system against atherosclerosis].
Yamashita S; Matsuzawa Y
Nihon Rinsho; 1993 Jun; 51(6):1684-91. PubMed ID: 8320848
[TBL] [Abstract][Full Text] [Related]
10. Alterations in composition and concentration of lipoproteins and elevated cholesteryl ester transfer in non-insulin-dependent diabetes mellitus (NIDDM).
Elchebly M; Porokhov B; Pulcini T; Berthezène F; Ponsin G
Atherosclerosis; 1996 Jun; 123(1-2):93-101. PubMed ID: 8782840
[TBL] [Abstract][Full Text] [Related]
11. Effects of feeding fish oil on the properties of lipoproteins isolated from rhesus monkeys consuming an atherogenic diet.
Soltys PA; Mazzone T; Wissler RW; Vahed S; Rangnekar V; Lukens J; Vesselinovitch D; Getz GS
Atherosclerosis; 1989 Apr; 76(2-3):103-15. PubMed ID: 2730707
[TBL] [Abstract][Full Text] [Related]
12. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
[TBL] [Abstract][Full Text] [Related]
13. [Disruption of the cholesterol-transport function of lipoproteins in the blood plasma of patients with ischemic heart disease].
Gerasimova EN; Perova NV; Kurdanov KhA; Polesskiĭ VA
Vopr Med Khim; 1984; 30(6):71-6. PubMed ID: 6528538
[TBL] [Abstract][Full Text] [Related]
14. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.
Chapman MJ; Guérin M; Bruckert E
Eur Heart J; 1998 Feb; 19 Suppl A():A24-30. PubMed ID: 9519339
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein physiology.
Ginsberg HN
Endocrinol Metab Clin North Am; 1998 Sep; 27(3):503-19. PubMed ID: 9785050
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans.
Schwartz CC; VandenBroek JM; Cooper PS
J Lipid Res; 2004 Sep; 45(9):1594-607. PubMed ID: 15145983
[TBL] [Abstract][Full Text] [Related]
17. Update on the pathogenesis of atherosclerosis.
Wissler RW
Am J Med; 1991 Jul; 91(1B):3S-9S. PubMed ID: 1867233
[TBL] [Abstract][Full Text] [Related]
18. High-density lipoprotein: a major risk factor for coronary atherosclerosis.
Miller NE
Baillieres Clin Endocrinol Metab; 1987 Aug; 1(3):603-22. PubMed ID: 3132134
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein composition in insulin-dependent diabetes mellitus with chronic renal failure: effect of kidney and pancreas transplantation.
Hughes TA; Gaber AO; Amiri HS; Wang X; Elmer DS; Winsett RP; Hathaway DK; Hughes SM; Ghawji M
Metabolism; 1994 Mar; 43(3):333-47. PubMed ID: 8139482
[TBL] [Abstract][Full Text] [Related]
20. Increases in dietary cholesterol and fat raise levels of apoprotein E-containing lipoproteins in the plasma of man.
Cole TG; Patsch W; Kuisk I; Gonen B; Schonfeld G
J Clin Endocrinol Metab; 1983 Jun; 56(6):1108-15. PubMed ID: 6841553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
